Novartis' orphan drug Tasigna wins EU expanded indication
Novartis | November 22, 2017
Novartis has claimed another regulatory milestone for its chronic myeloid leukaemia (CML) drug Tasigna (nilotinib), winning approval for its use to treat children in the EU.